1. Scrip
  2. >>Therapy Areas

Bayer Set To Sew Up HCC Market As RESORCE Hits Endpoint

 
• By Alexandra Shimmings

Top-line success for Bayer's trial of Stivarga in advanced liver cancer in patients who have progressed on its other therapy Nexavar gives the company an opportunity to dominate the market, but Stivarga's potential may be overshadowed by its drawbacks and looming competition.

Bayer HealthCare AG is poised to strengthen its hold on the liver cancer market after its multi-targeted anticancer Stivarga (regorafenib) met its primary endpoint in the Phase III RESORCE study testing it as a second-line treatment option for liver cancer patients whose disease has progressed after standard-of-care first-line therapy with the company's Nexavar (sorafenib).

Bayer plans to submit the data from RESORCE (regorafenib after sorafenib in patients with hepatocellular carcinoma) as the basis for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?